WHO nod to Sinopharm Covid-19 vaccine for emergency use

Published On 2021-05-08 08:01 GMT | Update On 2021-05-08 08:01 GMT

New Delhi: The World Health Organisation (WHO) on Friday approved the Chinese Sinopharm Covid-19 vaccine for emergency use, paving the way for it to be rolled out globally.

The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, a subsidiary of China National Biotec Group (CNBG).

"The addition of this vaccine has the potential to rapidly accelerate Covid-19 vaccine access for countries seeking to protect health workers and populations at risk," said Dr Mariangela Simao, WHO Assistant-Director General for Access to Health Products, in a statement.

"We urge the manufacturer to participate in the Covax Facility and contribute to the goal of more equitable vaccine distribution," she added.

This comes amid growing criticism of the Sinopharm vaccine.

The WHO's Emergency Unit Listing (EUL) allows countries to expedite their own regulatory approval to import and administer Covid-19 vaccines. It assesses the quality, safety and efficacy of Covid-19 vaccines, as well as risk management plans and programmatic suitability, such as cold chain requirements.

The global health body recommended the Chinese vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks. Vaccine efficacy for symptomatic and hospitalised disease was estimated to be 79 per cent, all age groups combined.

Few older adults over 60 years of age were enrolled in clinical trials, so efficacy could not be estimated in this age group, the WHO said. However, it did not recommend an upper age limit for the vaccine, saying that preliminary data and supportive immunogenicity data suggest the vaccine is likely to have a protective effect in older persons.

Vaccine experts around the globe have vehemently advised against Sinopharm, with the Shanghai-based doctor Tao Lina calling it the "most unsafe vaccine in the world".

In February this year, the Egyptian Health and Population Ministry issued a list of potential side-effects from the Sinopharm Covid-19 vaccine-pain, redness, stiffness and itching at the area of the vaccination, increase in body temperature and more, reported Newshub.ik

Pakistan Prime Minister Imran Khan and President Arif Alvi had tested positive for Covid-19 in March after taking the Sinopharm vaccine.

To make matters worse, one of the volunteers in Peru died after being injected with the Sinopharm vaccine, while one of the volunteers developed severe neurological side-effects associated with Guillain-Barre syndrome that causes nerve damage and often paralysis, during a clinical trial.

Article Source : ANI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

WHO nod to Sinopharm Covid-19 vaccine for emergency use

Similar News

Indian pharma market registers 7.9 percent growth in July: Report

Aragen appoints Aniel Khubchandani as CEO of Development and Manufacturing Solutions business

Mounjaro, Wegovy sales in India double on month in July

Eli Lilly Gets CDSCO Panel Nod for Ixekizumab Safety Label Update

CDSCO Panel Approves New Indications for Novo Nordisk's Semaglutide, Mandates PMS Study

Intas Pharma Gets Expert Panel Nod For PMS Data On Tofacitinib Ointment In Atopic Dermatitis

Axplora invests Euro 6.5 million to expand production capacity at Vizag site

NPPA Slapped Rs 9,950 Cr Penalty On Pharma Firms, Recovered Only 14.25%